Floatz logo

y-4 tables

Pregabalin

Neurodawn Pharmaceutical Co., Ltd.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pregabalin cohort.

Asset / SponsorPhaseRating
Pregabalin
Neurodawn Pharmaceutical Co., Ltd.
Phase 2CCC
Oxycodone
Beijing Tiantan Hospital
N/AD

Same molecule, other indications

y-4 tables is also rated in:

postherpetic neuralgiaDormant
CCC
Indicative ·
53 / 100
View asset →
Y-4Dormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →